Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

The weight loss market is evolving at an unprecedented rate with the advancements in anti-obesity medications, and 2025 will ...

USE of anti-obesity medications or AOMs and the associated demand for protein rich foods is a global trend set to benefit ...

This article does not attempt to predict the potential policies that the new administration and Congress might pursue or how ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

Calorie labels on food may lower calorie intake, but findings on alcohol are inconclusive, indicating a gap in research for ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cance ...

While weight-loss drugs were linked to lower risk of some conditions, they were also associated with some adverse health ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

Weight-loss drugs have been rolled out by the NHS, but many are buying them through social media and online pharmacies ...